Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
No Increase in Recurrence-Free Survival with Combined Regimen for Stage III/IVA Endometrial Cancer
30 března, 2021 1:01 amJune 3, 2017 A combined modality regimen did not increase recurrence-free survival (RFS) in patients with optimally debulked stage...
LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial
30 března, 2021 12:58 amMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Abstract number: 5500 Citation: J Clin Oncol 35,...
LION Findings Endorse Omitting Lymphadenectomy in Node-Negative Advanced Ovarian Cancer
30 března, 2021 12:53 amAccording to results of the large randomized LION Gynecologic Cancer Intergroup trial, routine pelvic and para-aortic lymphadenectomy offers no benefit...
NOVINKY Z ASCO – GYNEKOLOGICKÉ MALIGNITY
30 března, 2021 12:43 amTaké na letošním ročníku konference Americké společnosti klinické onkologie (ASCO) byl věnován prostor prezentacím zaměřeným na gynekologické nádory. Zaznělo několik sdělení, která...
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
30 března, 2021 12:39 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: 501 Citation: J Clin Oncol...
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
30 března, 2021 12:31 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Abstract number: 507 Citation: J Clin Oncol 35,...
Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A
30 března, 2021 12:23 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer-Metastatic Abstract number: 1008 Citation: J Clin Oncol 35, 2017...
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
30 března, 2021 12:17 amMeeting: 2017 ASCO Annual Meeting Track: Title:Breast Cancer-Metastatic Abstract number: 1002 Citation: J Clin Oncol 35, 2017...
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
30 března, 2021 12:00 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: LBA500 Citation: J Clin Oncol...
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
29 března, 2021 11:04 pmJune 5, 2017 Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to...